Loading patent…
AssigneesLudwig Institute for Cancer Research, University of Lausanne, Centre Hospitalier Universitaire Vaudois
InventorsGeorge COUKOS, Melita IRVING, Greta Maria Paola Giordano ATTIANESE
Estimating the term…
The invention relates to chimeric antigen receptors (CARs) targeting a cancer-associated antigen and their use for treatment of a tumor or cancer. In particular, the invention provides compositions and methods for treating diseases associated with the antigen NGcGM3. The invention also relates to CARs specific to NGcGM3, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to NGcGM3.
An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein said CAR comprises an anti-NGcGM3 binding domain, a transmembrane domain, and an endodomain.
-7. (canceled)
(canceled)
-36. (canceled)
An isolated chimeric antigen receptor (CAR) molecule, wherein said CAR comprises an anti-NGcGM3 binding domain, a transmembrane domain, and an endodomain.
-43. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-60. (canceled)
(canceled)
(canceled)
-69. (canceled)
-78. (canceled)
-82. (canceled)
-87. (canceled)
-93. (canceled)
-99. (canceled)
Dependencies are inferred from the claim text.